Veracyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Veracyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Veracyte Today - Breaking & Trending Today

Veracyte (NASDAQ:VCYT) Rating Reiterated by William Blair

William Blair reiterated their outperform rating on shares of Veracyte (NASDAQ:VCYT – Free Report) in a research report sent to investors on Friday, RTT News reports. William Blair also issued estimates for Veracyte’s Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at $0.00 EPS. A number of other brokerages have also issued reports on […] ....

Hong Kong , William Blair , Russell Investments Group Ltd , Veracyte Inc , Needham Company , International Assets Investment Management , Morgan Stanley , China Universal Asset Management Co , Hong Kong Ltd , Veracyte Company Profile , Free Report , Moderate Buy , Investments Group , Kong Ltd , Assets Investment Management , Universal Asset Management , Get Free Report , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Veracyte Daily , Nasdaq Vcyt ,

Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Veracyte ( NASDAQ:VCYT ) Full Year 2023 Results Key Financial Results Revenue: US$361.1m (up 22% from FY 2022). Net. ....

Revenues Beat Expectations , Earnings Per Share , Revenue Growth , Eracyte Revenues , Analyst Estimates ,

Needham & Company LLC Boosts Veracyte (NASDAQ:VCYT) Price Target to $33.00

Veracyte (NASDAQ:VCYT – Get Free Report) had its price target lifted by Needham & Company LLC from $30.00 to $33.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target suggests a potential upside of 35.58% from the […] ....

William Blair , Veracyte Inc , China Universal Asset Management Co , Morgan Stanley , Needham Company , Legato Capital Management , York Mellon Corp , Assetmark Inc , Get Free Report , Trading Down , Universal Asset Management , Capital Management , New York Mellon Corp , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Veracyte Daily , Nasdaq Vcyt , Boost Price Target , Needham Amp Company Llc ,

Veracyte Expects Higher Q4, FY23 Revenue Better Than View; To Acquire C2i Genomics

Biotechnology company, Veracyte, Inc. (VCYT) Monday announced that it expects higher revenue for fourth quarter and fiscal year 2023 mainly due to growth of its Afirma and Decipher businesses. ....

Veracyte Inc , C2i Genomics , 024 Report , Y23 Report ,

NinePointTwo Capital LLC Takes $265,000 Position in Veracyte, Inc. (NASDAQ:VCYT)

NinePointTwo Capital LLC acquired a new position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,437 shares of the biotechnology company’s stock, valued at approximately $265,000. A number of other institutional investors […] ....

United States , William Blair , Exchange Commission , First Hawaiian Bank , Eagle Asset Management Inc , Goldman Sachs Group , Morgan Stanley , Needham Company , Ninepointtwo Capital , Allspring Global Investments Holdings , Charles Schwab Investment Management Inc , Veracyte Inc , Free Report , Hawaiian Bank , Global Investments Holdings , Asset Management , Charles Schwab Investment Management , Schwab Investment Management , Get Free Report , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer ,